EyeGene Inc
185490
Company Profile
Business description
EyeGene Inc is a South Korea based bio-venture company. It researches and develops biopharmaceuticals. Its products include EG-Mirotin, EG-HPV, EGVac systems. It provides drugs for the treatment of age-related degenerative diseases. Its products target diabetic retinopathy.
Contact
Gangseo-gu, Seoul 401
B-dong 910 Gayang-dong
Seoul07528
KORT: +82 23221687
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
51
Stocks News & Analysis
stocks
ASX iron ore player downgraded ahead of earnings
Rising costs and delayed production drive fair value cut for ASX iron ore player.
stocks
Global tensions drive profitability for ASX energy provider
Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,311.90 | 125.80 | 1.37% |
| CAC 40 | 8,666.63 | 52.81 | 0.61% |
| DAX 40 | 26,202.35 | 201.04 | 0.77% |
| Dow JONES (US) | 54,085.88 | 907.47 | 1.71% |
| FTSE 100 | 10,879.38 | 21.68 | 0.20% |
| HKSE | 25,852.92 | 156.48 | -0.60% |
| NASDAQ | 26,584.99 | 671.10 | 2.59% |
| Nikkei 225 | 63,957.53 | 202.63 | 0.32% |
| NZX 50 Index | 13,903.46 | 128.53 | 0.93% |
| S&P 500 | 7,736.52 | 136.02 | 1.79% |
| S&P/ASX 200 | 9,145.80 | 122.80 | 1.36% |
| SSE Composite Index | 3,822.28 | 12.62 | 0.33% |